389TiP Identification of p.G12C KRAS mutation from exhaled breath of patients with lung cancer using FFP2 mask

Background: Young patients with non-small cell lung cancer (NSCLC) represent a distinct biological subgroup, frequently enriched with actionable oncogenic drivers.However, real-world survival data from Latin America are limited.We evaluated survival outcomes and prognostic factors in young versus older patients with NSCLC treated in Peru. Methods:We conducted a retrospective cohort study including patients with histologically confirmed NSCLC treated between 2018 and 2024 at a national reference cancer center.Patients were stratified by age at diagnosis (<45 vs 45 years).Overall survival (OS) was estimated using the Kaplan-Meier method.Multivariable Cox regression was performed adjusting for sex, ECOG performance status, smoking history, clinical stage, histology, molecular alterations and first-line treatment.Results: A total of 317 patients were included; 19.9% were younger than 45 years.The cohort was predominantly female (59.3%), never-smokers (85.5%) and had adenocarcinoma histology (95.6%).Advanced disease (stage III-IV) was present in 94.0% of cases.Actionable molecular alterations were identified in 69.4% of patients, most commonly EGFR mutations (48.3%).Younger patients showed a higher frequency of actionable mutations compared with older patients (70% vs 56%, p=0.038).After a median follow-up of 40.9 months, 92 deaths (29.0%) were recorded.In adjusted analysis, young age was not associated with worse OS (adjusted HR 1.32; 95% CI 0.79-2.21;p=0.29).Former smoking history was the only independent predictor of inferior OS (adjusted HR 2.38; p=0.018).Conclusions: Young age at NSCLC diagnosis was not associated with inferior survival.Despite advanced-stage presentation, younger patients exhibited a high prevalence of actionable oncogenic drivers, supporting routine comprehensive molecular profiling.These results provide robust regional evidence and reinforce the importance of precision oncology in underrepresented populations.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106702
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

389TiP Identification of p.G12C KRAS mutation from exhaled breath of patients with lung cancer using FFP2 mask

Jolanda Palmisani, Alessia Di Gilio, Fabio Sallustio, Anna Lasorella et al.
ESMO Open
Lung Cancer Treatments and Mutations
article

389TiP Identification of p.G12C KRAS mutation from exhaled breath of patients with lung cancer using FFP2 mask

Jolanda Palmisani, Alessia Di Gilio, Fabio Sallustio, Anna Lasorella, Rosanna Lacalamita, Lucio Pastore, M. Mazzola, Doron Tolomeo, Valentina Pizzillo, Michele Sansone, S. Tommasi, C.T. Storlazzi, M.R. Nisi, A. Catino, D. Galetta, M. Montrone, G. de Gennaro, E.S. Montagna, A.V. Quarato
article en

Abstract

Background: Young patients with non-small cell lung cancer (NSCLC) represent a distinct biological subgroup, frequently enriched with actionable oncogenic drivers.However, real-world survival data from Latin America are limited.We evaluated survival outcomes and prognostic factors in young versus older patients with NSCLC treated in Peru. Methods:We conducted a retrospective cohort study including patients with histologically confirmed NSCLC treated between 2018 and 2024 at a national reference cancer center.Patients were stratified by age at diagnosis (<45 vs 45 years).Overall survival (OS) was estimated using the Kaplan-Meier method.Multivariable Cox regression was performed adjusting for sex, ECOG performance status, smoking history, clinical stage, histology, molecular alterations and first-line treatment.Results: A total of 317 patients were included; 19.9% were younger than 45 years.The cohort was predominantly female (59.3%), never-smokers (85.5%) and had adenocarcinoma histology (95.6%).Advanced disease (stage III-IV) was present in 94.0% of cases.Actionable molecular alterations were identified in 69.4% of patients, most commonly EGFR mutations (48.3%).Younger patients showed a higher frequency of actionable mutations compared with older patients (70% vs 56%, p=0.038).After a median follow-up of 40.9 months, 92 deaths (29.0%) were recorded.In adjusted analysis, young age was not associated with worse OS (adjusted HR 1.32; 95% CI 0.79-2.21;p=0.29).Former smoking history was the only independent predictor of inferior OS (adjusted HR 2.38; p=0.018).Conclusions: Young age at NSCLC diagnosis was not associated with inferior survival.Despite advanced-stage presentation, younger patients exhibited a high prevalence of actionable oncogenic drivers, supporting routine comprehensive molecular profiling.These results provide robust regional evidence and reinforce the importance of precision oncology in underrepresented populations.

ESMO OpenVol. 11
Istituto Tumori Bari (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University of Bari Aldo Moro (IT)
Good health and well-being
Openalex Percentile: Top 19%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.